Vertex Pharmaceuticals Inc / Ma: Form 10-Q for the period ended Jun 30, 2016
Filed with the SEC on Aug 1, 2016 and accepted by EDGAR at Aug 1, 2016, 20:51 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2016-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2016-04-01 to 2016-06-30 | $431.6m | us-gaap:Revenues |
| Revenue | 6 months2016-01-01 to 2016-06-30 | $829.7m | us-gaap:Revenues |
| Cost of revenue | 3 months2016-04-01 to 2016-06-30 | $44.2m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 6 months2016-01-01 to 2016-06-30 | $93.9m | us-gaap:CostOfGoodsSold |
| Research and development | 3 months2016-04-01 to 2016-06-30 | $271.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2016-01-01 to 2016-06-30 | $526.9m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2016-04-01 to 2016-06-30 | $111.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2016-01-01 to 2016-06-30 | $216.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2016-04-01 to 2016-06-30 | $3.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2016-01-01 to 2016-06-30 | −$11.0m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2016-04-01 to 2016-06-30 | $18.1m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2016-01-01 to 2016-06-30 | $23.6m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2016-04-01 to 2016-06-30 | −$64.5m | us-gaap:NetIncomeLoss |
| Net income | 6 months2016-01-01 to 2016-06-30 | −$106.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2016-04-01 to 2016-06-30 | −$0.26 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2016-01-01 to 2016-06-30 | −$0.43 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2016-04-01 to 2016-06-30 | −$0.26 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2016-01-01 to 2016-06-30 | −$0.43 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2016-04-01 to 2016-06-30 | 244,482,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2016-01-01 to 2016-06-30 | 244,124,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2016-01-01 to 2016-06-30 | $25.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2016-01-01 to 2016-06-30 | $27.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2016-06-30 | $605.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2016-06-30 | $1.45bn | us-gaap:AssetsCurrent |
| Total assets | At period end2016-06-30 | $2.55bn | us-gaap:Assets |
| Current liabilities | At period end2016-06-30 | $622.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2016-06-30 | $1.38bn | us-gaap:Liabilities |
| Shareholders' equity | At period end2016-06-30 | $981.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000875320-16-000091. Last ingested by Listed: Nov 6, 2026, 12:56 ET. Listed shows no prices and gives no investment advice.